Related content

Immuntherapie des metastasierten Nierenzellkarzinoms mit Interleukin-2, Interferon-α2a und Erythropoetin-β

By Schenck M.   Börgermann C.   Jäger T.   Dorp F.   Sperling H.   Rübben H.   Lümmen G.  

Der Urologe A, Vol. 46, Iss. 5, 2007-05 ,pp. : 528-534

Springer Publishing Company

Access to resources Recommend Favorite

Effects of interferon- and interleukin-2 on the expressions of matrix metalloproteinases and their inhibitors in human renal cell carcinoma cells

By Kim S.   Lee J.   Lee I.   Shin K.   Park H.   Lee T.   Woo Y.   Jang S.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 182-182

Elsevier

Access to resources Recommend Favorite

Bedeutung der Immunochemotherapie für das Überleben von Patienten mit metastasiertem Nierenzellkarzinom: Eine retrospektive Studie der Therapiegruppen Interferon-α2a/Vinblastin vs. Interferon-α2a/Interleukin-2/5-Fluorouracil

By May M.   Helke C.   Bock M.   Hoschke B.  

Der Urologe A, Vol. 43, Iss. 9, 2004-09 ,pp. : 1111-1119

Springer Publishing Company

Access to resources Recommend Favorite

Prehospital sedation: practical application

By Jeremie N.   Ricard-Hibon A.   Facon A.   Lenfant F.  

Annales Francaises d'Anesthesie et de Reanimation, Vol. 22, Iss. 9, 2003-11 ,pp. : 831-831

Elsevier

Access to resources Recommend Favorite

Blood profile of interleukin-4 and gamma-interferon in patients with benign prostatic hyperplasia

By Ebralidze D.   Kochiashvii D.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 20-20

Elsevier

Access to resources Recommend Favorite